Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Pancreatic Neoplasm
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 14 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prediabetes, Type 2 Diabetes
Interventions: Vitamin D (Cholecalciferol), Placebo; Dietary Supplement · Other
Lead sponsor: Tufts Medical Center; Other
Eligibility: 30 Years and older
Enrollment: 2,423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions: Computed Tomography, Magnetic Resonance Imaging, Tazemetostat; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 581
States / cities: Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more

Conditions: Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Neoplasms
Interventions: Aroplatin (Liposomal NDDP, L-NDDP); Drug
Lead sponsor: Aronex Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: AdV-tk, Valacyclovir; Biological · Drug
Lead sponsor: Candel Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Duarte, California • La Jolla, California • Columbus, Ohio

Conditions: Pancreatic Tumors
Interventions: EUS Guided Fine Needle Aspiration, EUS Guided EchoBrush Sampling; Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: DS-7309, placebo, Metformin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Lifestyle Counseling, Educational Control Arm; Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 19 Years to 75 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Diabetes, Gestational Diabetes
Interventions: human insulin, insulin NPH, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Diabetes Mellitus
Interventions: Pamphlet, Video; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Aurora, Colorado • Chicago, Illinois

Conditions: Tumor
Interventions: belinostat, 5-Fluorouracil (5-FU); Drug
Lead sponsor: Valerio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire

Conditions: Type 2 Diabetes, Renal Impairment
Interventions: PF-07081532; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Tampa, Florida • Saint Paul, Minnesota

Conditions: Cystic Fibrosis
Interventions: RELiZORB (immobilized lipase) cartridge, Impact Peptide 1.5; Device · Other
Lead sponsor: Alcresta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Hollywood, Florida • Boise, Idaho • Indianapolis, Indiana + 7 more

Conditions: Recurrent Ovarian Epithelial Cancer
Interventions: oxaliplatin, topotecan; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: PreDiabetes, Obesity, Childhood
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 8 Years to 22 Years
Enrollment: 772 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Tumor, Ovarian Cancer
Interventions: NKTR-102 q14d, NKTR-102 q21d; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 11
States / cities: Highland, California • Los Angeles, California • Newport Beach, California + 8 more

Conditions: Growth Hormone Deficiency
Interventions: Somavaratan; Drug
Lead sponsor: Versartis Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer, Surgical Wound Dehiscence, Traumatic Wounds
Interventions: Study Device Debridement, SOC Debridement; Device
Lead sponsor: Medaxis, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Bradenton, Florida

Conditions: Obesity, Diabetes, Nutrition, Physical Health
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 12 Years to 17 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Milwaukee and Madison, Wisconsin

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Interventions: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more

Conditions: Diabetes Mellitus, Type 2, Diabetes Complications
Interventions: Diabetes Tune-Up Group; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 2 Diabetes Mellitus
Interventions: Fasiglifam, Placebo to fasiglifam; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Goodyear, Arizona • Long Beach, California • Los Angeles, California + 44 more

Conditions: Type 1 Diabetes
Interventions: DailyDose Decision Support; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions: Cetuximab:, Paclitaxel, Carboplatin; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Search by objective public record fields.

Endoscopic Ultrasound Radiofrequency Ablation, Database Repository

Vitamin D and Type 2 Diabetes Study

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in Diagnosis of Cystic Pancreatic Tumors

Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study

Empowering Rural African American Women and Communities to Improve Diabetes Outcomes

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

Encouraging Patient-Centered Communication in Clinical Video Telehealth Visits

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study

Oxaliplatin and Topotecan in Advance Ovarian Cancer

Conventional and Metabolomic Predictors of Prediabetes & Insulin Resistance

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center

Effects of Environmental Opportunities and Barriers on Physical Activity, Fitness, and Health in Hispanic Children in Wisconsin

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Electronic Diabetes Tune-Up Group (eDTU) for African Americans

Fasiglifam 25 mg BID vs 50 mg QD

Assessment of a Decision Support Tool in Participants With Type 1 Diabetes

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer